Duality Advisers’s Cytokinetics CYTK Stock Holding History

Duality Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,469	Closed	-$931K	–	552
2023 Q1	$931K	Buy	+26,469	New	+$1.08M	0.11%	313
2022 Q4	–	Sell	-57,037	Closed	-$2.76M	–	624
2022 Q3	$2.76M	Buy	57,037 +25,908	+83%	+$1.25M	0.3%	117
2022 Q2	$1.22M	Buy	+31,129	New	+$1.25M	0.12%	313

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Duality Advisers's CYTK Position: Q2 2023 in Review

Duality Advisers sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 26,469 shares — an estimated $931K sold.

Duality Advisers first reported a position in CYTK in Q2 2022 and held it in 3 quarters. The position peaked at $2.76M in Q3 2022. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

Duality Advisers reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
Duality Advisers sold 26,469 Cytokinetics shares in Q2 2023, an estimated $931K.
Duality Advisers first reported a position in Cytokinetics in Q2 2022 and held it in 3 quarters.
Duality Advisers's Cytokinetics position peaked at $2.76M in Q3 2022.
253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Duality Advisers's 13F filing for Q2 2023, filed 31 Jul 2023.